Navigation Links
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
Date:2/10/2009

-Cohort 1 Data Promising for Type 2 Diabetes-

PLYMOUTH MEETING, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. Mr. Jack Armstrong, President and CEO of Genaera, presented data from the first of three cohorts in an ascending multiple dose study of MSI-1436 (Study 102), during the BIO CEO & Investor Conference in New York.

Data from cohort 1, in which eight doses of 3 mg/m2 of MSI-1436 were administered over 21 days to overweight and obese type 2 diabetic subjects, demonstrated meaningful improvement in four primary outcomes used to evaluate type 2 diabetes, including:

  • A 9.5% decrease in fasting blood glucose with a resulting 17% differential compared to placebo subjects in the same cohort;
  • A 7% decrease in the area under the curve during the oral glucose tolerance test;
  • An 11.3% decrease in serum fructosamine, which is used to monitor short-term (2-3 weeks) blood sugar control; and
  • A 0.4% decrease in hemoglobin A1C (HbA1C), used to monitor longer-term (2-3 months) blood sugar control.

"It is very exciting to see a believable biologic response to MSI-1436 in cohort 1 of Study 102. While 3 mg/m2 of drug was thought to be a sub-therapeutic dose, the data has demonstrated otherwise. We are currently completing the in-house portion of the second cohort of this study evaluating 6 mg/m2 of MSI-1436 and the initial results support proceeding to the 10 mg/m2 cohort which will begin later this month. Final Study 102 data is expected in the second quarter," commented Mr. Armstrong. "MSI-1436 continues to exhibit promise as the only PTP1B inhibitor in development to simultaneously treat both type 2 diabetes and obesity. Our recent identification of a novel binding site we believe is the key to its selectivity and safety to date. We are anxious to begin our first study of subcutaneously administered MSI-1436 to human subjects, which is planned for later this year."

In Cohort 1 of Study 102, five subjects received MSI-1436 while two subjects received placebo, with results suggesting that MSI-1436 is well-tolerated, with no serious adverse events, no severe adverse events and no dose-limiting toxicities reported. In addition to the favorable adverse event profile seen in the cohort, the multiple-dose PK of MSI-1436 was found to be similar to the PK profiles following single intravenous dosing in two previous phase 1 studies.

About Trodusquemine (MSI-1436)

Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting both central and peripheral PTP1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Initial clinical studies of trodusquemine in obese and overweight subjects has provided early indicators of weight loss and improved glucose control. These results confirm previous work in animal models which demonstrated significant weight loss without metabolic rebound, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
2. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
3. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
6. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
7. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
8. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
10. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
11. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 The Global ... understanding and access to partnering deals and agreements entered ... Trends in partnering deals - Top deals by value ... of development, technology type The report provides understanding ... into by the world,s leading healthcare companies. The ...
(Date:1/19/2017)... Jan. 18, 2017 The Academy of ... Drug Administration (FDA) for its release today of ... health decision makers can proactively share clinical and ... well as emerging therapies awaiting FDA approval. ... recommendations that AMCP developed during two multi-stakeholder meetings ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 ... "Breast Imaging Technologies Market by Type: Global Opportunity Analysis and ... market size was valued at $2,544 million in 2015 and ... a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in 2015. Ionizing ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate ... in 2017 who are passionate about making a difference in the lives of ... in Tampa, UMA, a nonprofit healthcare educational institution, has more than 30,000 alumni ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance ... commercial and residential clients in the California Bay Area, is launching a charity drive ... the region. , Heart disease is the primary killer of adult men and women ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Tribble Insurance ... to the eastern Virginia region, is inaugurating a charity event to honor Chad Phillip ... While on duty last year, Chad Phillip Dermyer and his fellow officers were conducting ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... St. Catherine’s ... Center. , Siena Center is a skilled nursing facility on the grounds of the ... semiprivate rooms. It recently was voted the best nursing home in Mississippi for the ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Spring Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries ... . , Educational grants totaling $15,000 will be awarded for the best ...
Breaking Medicine News(10 mins):